The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1G93A and TDP-43Q331K transgenic mouse models of ALS

The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1G93A and TDP-43Q331K transgenic mouse models of ALS

Abstract GLP-1 receptor agonists used for the treatment of diabetes, have shown some neuroprotective effects in cellular and animal models of Alzheimer’s disease (AD) and Parkinson’s disease (PD). There are currently few studies investigating GLP-1 receptor agonists in the treatment of ALS, where th...

Full description

Saved in:
Bibliographic Details
Main Authors: Amy Keerie, Heledd Brown-Wright, Isaac Kirkland, Andrew Grierson, James J. P. Alix, Christian Holscher, Richard J. Mead
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/8ad89c55f0164a14a6f498f5d3f6500b
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items